CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
Life Sciences Review
US
EUROPE
APAC
CANADA

About Us

Conference

Partner With Us

  • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Drug Discovery
    Antibodies
    BioTech
    Cell and Gene Therapy
    Clinical Trial
    Drug Discovery and Development
    Life Science AI
    Regenerative Medicine
    Therapeutics
  • Biomanufacturing
    Biomanufacturing
    Biomarker
    Bioprocessing
    Blood Bank
    CDMO
    Clinical Laboratory
    CRO
    Life Science Testing
    Skin Care
    Supplements
  • Business Services
    Life Science Consulting
    Life Science Facility Service
    Life Science Financial Services
    Life Science Marketing
    Life Science Recruitment Firms
    Pharma Wholesale and Distribution
    Pharmacy Management
    Regulatory and Compliance
    Regulatory Services
    Technologies and Software
  • Leadership Perspectives
  • Innovation Insights
  • Research
  • News
  • Magazines
  • CXO Awards
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

Advancing Digital Maturity in Life Science Validation

The life science industry is moving from paper-based validation to intelligent, continuous processes, leveraging digital transformation and predictive technologies to improve quality and ensure compliance. 

By

Life Sciences Review | Wednesday, March 18, 2026

The life science industry, long defined by precision, safety, and regulatory rigor, is experiencing its most significant operational transformation in decades. Validation—the documented assurance that a method, system, or piece of equipment consistently delivers the expected results—is shifting from static, paper-based records to intelligent, continuous processes. This evolution charts the industry’s journey from traditional binders to predictive, digital platforms. It can be framed as a four-stage progression, with each stage characterized by distinct processes, technologies, and evolving interpretations of what “validation” truly entails.


The traditional approach to validation has long been rooted in analog, paper-based processes, defined by manual execution and physical documentation. In this conventional model, validation protocols are authored using word processors, printed, and circulated for review and approval through handwritten “wet signatures.” On the manufacturing floor, test scripts are performed with pen and clipboard in hand, with deviations, observations, and data points recorded manually. Traceability matrices—linking requirements to test cases—are typically maintained as complex spreadsheets, updated laboriously by hand.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.


The culmination of this process is a physical validation package: a collection of binders containing signed protocols, test results, and summary reports. These documents are often stored in filing cabinets for years, awaiting potential audits or inspections. While foundational to past operations, this method is inherently labor-intensive, susceptible to human error — such as transcription mistakes or missing signatures —and introduces significant operational friction, particularly when managing change controls or conducting post-approval reviews.


The Digitized Transition


The initial step toward digitalization is often a lateral move rather than a transformative one. In this “paper-on-glass” phase, organizations replace physical forms with digital equivalents, yet the core processes remain essentially unchanged. Paper-based documents are converted to digital formats—such as fillable PDFs or basic electronic forms—that are accessed via tablets or terminals. Operators and validation engineers enter data by typing rather than writing, with the system offering limited enhancements such as timestamps, basic data-entry validation (e.g., flagging out-of-range temperatures), and electronic signatures.


While this stage reduces paper consumption and can modestly accelerate data entry, it often creates “digital silos” that remain isolated from critical quality systems, such as change control or CAPA (Corrective and Preventive Action). The workflow remains linear and manually driven, with digital files merely replacing physical folders. Consequently, this stage represents a digital façade—one that offers incremental efficiency gains without delivering meaningful improvements in data integrity, process connectivity, or overall operational intelligence.


The Digitalized Platform


This stage represents the first true digital transformation—an evolution from isolated documents to an integrated, data-centric platform. It is defined by adopting mature Validation Lifecycle Management Systems (VLMS) and integrated electronic Quality Management Systems (eQMS), in which validation ceases to be a static document and becomes a managed, automated workflow. These systems enforce standardization by generating validation protocols from approved, pre-validated templates and managing the entire lifecycle — from authoring and collaborative review to electronic approval, test execution, deviation management, and final reporting.


The resulting “validation package” exists as a secure, queryable dataset within a unified system. Data integrity is embedded by design, governed by 21 CFR Part 11 and EU Annex 11 principles, with immutable audit trails and secure electronic signatures ensuring full compliance. Moreover, integration drives intelligence across operations—a change control record can automatically initiate corresponding validation activities, while an electronic equipment logbook remains directly linked to the equipment’s validation status. A failed verification test within the eQMS can even trigger an automatic hold on affected equipment, preventing its use in manufacturing. In this stage, validation evolves into a connected, traceable, and compliant digital ecosystem that seamlessly bridges fragmented, manual processes.


The Intelligent Transformation


The final stage of maturity signifies a paradigm shift from periodic validation to continuous assurance—transforming validation from a static, retrospective exercise into a dynamic, predictive, and automated component of daily operations. At this level, the framework is anchored in Continuous Process Verification (CPV), a methodology that leverages real-time data to ensure processes remain consistently controlled throughout routine production. Rather than validating a process through a fixed number of batches and archiving the results, CPV enables ongoing monitoring of Critical Process Parameters (CPPs) and Critical Quality Attributes (CQAs), ensuring continuous compliance and performance stability.


Advanced digital technologies power this evolution. Digital Twins—virtual replicas of physical systems—facilitate virtual validation, enabling issues to be identified and resolved before any physical resources are expended. Complementing this, Internet of Things (IoT) sensors provide a constant stream of real-time operational data from the production floor, creating a seamless feedback loop. AI and Machine Learning (ML) algorithms serve as the analytical core, interpreting vast and complex data patterns to predict potential deviations before they occur. In this model, validation transcends its traditional purpose of confirming system functionality—it anticipates failures and enables proactive intervention. The result is an autonomous, self-correcting validation ecosystem that ensures quality by design and in real time.


The evolution from paper to platform is more than an IT upgrade; it is a strategic re-engineering of quality itself. As the industry moves along this curve, it leaves behind the static, reactive world of paper. It embraces a predictive future where compliance and efficiency are not competing goals but the twin outcomes of true digital maturity.


More in News

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Autologous and Allogeneic Models Push Cell Therapy Toward Different Development Paths

Cell therapy product development is becoming more segmented as autologous and allogeneic products place different demands on design, manufacturing and commercialization. Developers can no longer discuss the sector as one uniform category. Product strategy depends heavily on whether cells come from the patient or from a donor source. Autologous therapies are often built around individualized production. A patient’s own cells are collected, processed and returned as a therapy. This model can create a strong biological fit, but it also places pressure on scheduling, chain of identity, release timelines and site coordination. Every patient-specific batch becomes both a treatment and a manufacturing event. Allogeneic therapies take a different approach. Instead of using each patient's own cells, they rely on donor-derived or engineered cells that can be produced in larger batches and supplied to more patients. This model has the potential to improve access and make therapies more widely available, provided quality, immune compatibility and long-term performance are carefully managed. At the same time, it brings its own set of challenges, including how cells are sourced, how consistently they can be expanded during manufacturing, how they are stored and how different patients may respond to the treatment. Industry analysis from Thermo Fisher Scientific’s Patheon unit notes that autologous therapies require individualized handling because each treatment is tailored to a patient’s cells, while allogeneic therapies must ensure consistent quality and address immune compatibility across recipients. These differences influence product development from the very beginning. For autologous therapies, developers often concentrate on coordinating the entire vein-to-vein process, including logistics, site readiness, rapid release testing and making sure each patient's cells move through the system efficiently. Developers of allogeneic therapies face a different set of priorities, with greater attention on master cell banks, consistency between production batches, inventory management and large-scale quality control. Each approach comes with its own operational challenges, costs and risks that need to be managed throughout development. Manufacturing partners are therefore becoming more specialized. A partner supporting allogeneic production may need scale-up expertise and robust batch release processes. Developers must choose partners based on model fit, not general cell therapy experience alone. Digital systems are becoming important in both pathways. Developers need data continuity from cell collection through manufacturing and administration. Gaps in records can create delays and weaken confidence. Better data handling can support quality review and long-term learning across batches or patient cases. The future of cell therapy product development will likely involve both models advancing in parallel. Autologous and allogeneic approaches solve different problems and face different barriers. The companies best positioned will be those that align biology, manufacturing design, clinical planning and commercial delivery around the specific therapy model they are building. ...Read more
Life Sciences Review
Follow on LinkedIn

About

  • Home
  • About Us
  • Partner With Us

Stay Connected

  • Subscribe
  • Newsletter
  • Sitemap

Contact Us

  • editor@lifesciencesreview.com
  • sales@lifesciencesreview.com
  • marketing@lifesciencesreview.com

Legal

  • Editorial Policy
  • Privacy Policy
  • Terms of Use

© 2026 Life Sciences Review. All rights reserved.

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/advancing-digital-maturity-in-life-science-validation-nwid-3034.html